Jagsonpal Pharmaceuticals Announces Q4 and Full Year Results for FY26

Jagsonpal Pharmaceuticals Announces Q4 and Full Year Results for FY26​

Jagsonpal Pharmaceuticals Limited has announced its audited financial results for the quarter and the full year ended March 31, 2026. The company reported robust growth across its key metrics, highlighted by a 10% acceleration in revenue during the fourth quarter (Q4FY26) and a significant increase in net profits for the fiscal year 2026 (FY26).

Financial Performance Review​

The financial data for the quarter and full year is presented below, showing solid year-over-year (YoY) growth momentum.

Key Strategic Highlights​

The company announced several shareholder-focused actions, including a recommendation for enhanced dividends and a buyback program.

The Board has recommended a higher dividend distribution at 200% (including a 75% special dividend). Furthermore, Jagsonpal Pharmaceuticals plans to launch a proposed share buyback of up to 16 lakh equity shares, with a total outlay of ₹40 Cr. This buyback aims to improve the Return on Capital Employed (ROCE) from 22.0% to 25.7% and the Return on Equity (ROE) from 16.2% to 18.9%.

In terms of cash flow, the cash balance stood at ₹1,907 Mn as of March 31, 2026, marking an increase of ₹451 Mn and underscoring strong operational and financial discipline.

Management Commentary on Growth​

Manish Gupta, Managing Director and CEO of Jagsonpal Pharmaceuticals Limited, commented on the performance, stating that the business regained traction in Q4, achieving 10% growth, which he attributed to sharper strategic execution.

He noted that the company's yearly revenue grew by 7%, while the operating net profit grew by 19% in the same period, culminating in a healthy cash position of ₹191 crores.

Mr. Gupta confirmed that these shareholder-centric actions—the recommended 200% dividend and the proposed ₹40 crore buyback at ₹250 per share—reflect the company's confidence in future growth momentum.

"We are confident of continued acceleration on all parameters given our focus on organic growth through improved MR productivity, strengthening key brands, and launching strategic new products," he added.

Operational Strengths​

The company's performance is supported by strong internal execution and sustained operational discipline. Operational EBITDA for the full year reached ₹609 Mn, maintaining a margin of 21.2%. For Q4, the EBITDA stood at ₹106 Mn, demonstrating efficient cost management.

The firm maintains a robust presence across key therapeutic segments, including Gynecology, Orthopaedics, and Pediatrics, and operates with an asset-light model, utilizing outsourced R&D and Contract Manufacturing to facilitate scaled growth without excessive capital strain.

JAGSNPHARM Stock Price Movement​

Today, Jagsonpal Pharmaceuticals Limited shares gained ₹4.45, finishing at ₹203.67 after a steady rally in post-market trading. The stock found support on momentum today, with a trading volume reaching 148,205 shares.